BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study
European Journal of Endocrinology · 2024
DOI: 10.1093/ejendo/lvae091 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Dario De Alcubierre und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Rome F-00161, Italy. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Craniopharyngioma, Pyridones, Pituitary Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objective
Targeted therapy (TT) with BRAF/MEK inhibitors has emerged as a potential treatment in papillary craniopharyngiomas (PCPs). However, standardized data on large cohorts are lacking. Our study aimed to assess real-life efficacy and safety of BRAF/MEK inhibition in patients with PCPs.
Design
Retrospective French multicenter study involving BRAF V600E–mutated PCP patients, treated with BRAF/MEK inhibitor combination dabrafenib and trametinib, from April 2019 to July 2023.
Methods
Objective response and clinical and safety outcomes were assessed after 3 months and at the last available follow-up during TT.
Results
Sixteen patients (8 females, mean age 50.5 ± 15.75 years), receiving either neoadjuvant therapy (NEO) for non-resectable tumors (n = 6), post-surgical adjuvant therapy (ADJ; n = 8), or palliative therapy (PAL) following failure of multimodal treatment (n = 2), were included. At the last follow-up (mean 7.6 ± 5.3 months), 12 patients showed subtotal response, 3 exhibited partial response, and 1 maintained stable disease. Mean volume reduction was 88.9 ± 4.4%, 73.3 ± 23.4%, and 91.8 ± 4.3% in the NEO, ADJ, and PAL groups, respectively. Targeted therapy resolved headaches in 5/5 patients and visual impairment in 6/9; 2/3 patients had improved neurological symptoms, 1/4 presented weight loss, and 2/14 recovered endocrine function. Targeted therapy was well-tolerated in 62.5% of cases; adverse events led to treatment discontinuation in 5 patients and definitive discontinuation in 3 cases.
Conclusions
In this study, 94% of patients showed partial response or better to TT. Adverse events were acceptable. Further research is needed to establish standardized protocols; however, these results advocate for a NEO approach in invasive PCPs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, Sapienza University of Rome, Rome F-00161, Italy.
- Cancer Research Center of Lyon, Inserm U1052, CNRS UMR5286, Lyon F-69008, France.
- Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, Bron F-69677, France.
- CHU de Poitiers, ProDiCeT, Université de Poitiers, Poitiers F-86073, France.
- Oncology Department, Poitiers University Hospital, Poitiers F-86000, France.
- CHU d'Angers, Angers F-49100, France.
ORCID-Profile: Dario De Alcubierre, Camille Sergeant, François Ducray, Bertrand Baussart, Gerald Raverot
Zitieren
APA
De Alcubierre, D., Gkasdaris, G., Mordrel, M., Joncour, A., Briet, C., Almairac, F., Boetto, J., Mouly, C., Larrieu-Ciron, D., Vasiljevic, A., Villa, C., Sergeant, C., Ducray, F., Feuvret, L., Chanson, P., Baussart, B., Raverot, G., & Jouanneau, E. (2024). BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae091
Vancouver
De Alcubierre D, Gkasdaris G, Mordrel M, Joncour A, Briet C, Almairac F, et al. BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae091
BibTeX
@article{DeAlcubierre2024,
author = {De Alcubierre, Dario and Gkasdaris, Grigorios and Mordrel, Margaux and Joncour, Anthony and Briet, Claire and Almairac, Fabien and Boetto, Julien and Mouly, Celine and Larrieu-Ciron, Delphine and Vasiljevic, Alexandre and Villa, Chiara and Sergeant, Camille and Ducray, François and Feuvret, Loic and Chanson, Philippe and Baussart, Bertrand and Raverot, Gerald and Jouanneau, Emmanuel},
title = {BRAF and MEK inhibitor targeted therapy in papillary craniopharyngiomas: a cohort study},
journal = {European Journal of Endocrinology},
year = {2024},
doi = {10.1093/ejendo/lvae091}
}
EUVIMED